GEICAM/2003-11 CIBOMA TRIAL

In the mini-oral abstract session, Prof Federico Rojo presented the results of the CIBOMA-GEICAM trial, which assessed the benefit of capecitabine in early-stage triple-negative breast cancer following standard neoadjuvant chemotherapy. In this video, he comments on this presentation. The main goal of this pre-planned analysis was to identify the non-basal phenotype by comparing various methods, including PAM-50, surrogate immunochemical subtyping based on cytokeratin 5 and 6 plus EGFR expression, and the immunochemical assay for FOXC1.

FOXC1 was assayed using a standard method with a semi-quantitative algorithm that combined the percentage of tumour cells and the intensity of the scoring to define the non-basal phenotype.

The trial’s key finding was that the benefit of capecitabine is correlated with the detection of the non-basal phenotype. This result is significant because it suggests that triple-negative breast cancer can be classified into basal and non-basal subtypes, which can inform treatment decisions regarding the use of capecitabine. Identifying non-basal tumours that benefit from adjuvant capecitabine could potentially improve outcomes for patients with triple-negative breast cancer by providing a more tailored therapeutic approach.